<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03940469</url>
  </required_header>
  <id_info>
    <org_study_id>Interscalene Dexmedetomidine</org_study_id>
    <nct_id>NCT03940469</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Versus Dexamethasone With Levobupivacaine in Interscalene Block</brief_title>
  <acronym>IBBB</acronym>
  <official_title>Comparison Between Dexmedetomidine Versus Dexamethasone With Levobupivacaine in Ultrasound Guided Interscalene Block During Shoulder Arthroscopy: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menoufia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mamdoh Elsayed Lotfy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Osama Abdallah Elsharkawy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Basma Abdelhamid Fathy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Menoufia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators compared between dexamethasone and dexmedetomidine when added to
      levobupivacaine in the quality and duration of ultrasound-guided interscalene block during
      shoulder arthroscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sixty patients were enrolled and divided into three groups 20 each, Group C received 35ml
      levobupivacaine+2ml normal saline under ultrasound guided interscalene block. Group H
      received 35ml levobupivacaine+8mg dexamethasone under ultrasound guided interscalene block.
      Group D received 35ml levobupivacaine+100umg dexmedetomidine+1ml normal saline. The primary
      outcome was the postoperative pain which was assessed by Visual analog score(VAS), the
      secondary outcomes were the onset and duration of sensory and motor block, the total amount
      of analgesic requirement, and blood cortisol level.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 3, 2016</start_date>
  <completion_date type="Actual">January 1, 2019</completion_date>
  <primary_completion_date type="Actual">January 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>three groups 20 each, Group C received 35ml levobupivacaine+2ml normal saline under ultrasound guided interscalene block. Group H received 35ml levobupivacaine+8mg dexamethasone under ultrasound guided interscalene block. Group D received 35ml levobupivacaine+100umg dexmedetomidine+1ml normal saline.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>both the patients and the observer were blind to the treatment groups</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in postoperative analgesia</measure>
    <time_frame>During first 2 days after surgery</time_frame>
    <description>Assessed by measuring severity of pain by visual analog score(score 0 to 10 cm with 0= no pain and 10=worst pain imaginable).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative analgesic requirement</measure>
    <time_frame>During first 2 days after surgery</time_frame>
    <description>Total amount of paracetamol required in mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic parameter</measure>
    <time_frame>During first 2 days after surgery</time_frame>
    <description>Heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic parameter</measure>
    <time_frame>During first 2 days after surgery</time_frame>
    <description>Mean arterial blood pressure</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Postoperative Analgesia</condition>
  <condition>Postoperative Complications</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>received 35ml levobupivacaine+2ml normal saline under ultrasound guided interscalene block.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>received 35ml levobupivacaine+8mg dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmeteomidine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>received 35ml levobupivacaine+100umg dexmedetomidine+1ml normal saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>2 ml normal saline</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Injection</intervention_name>
    <description>8 mg dexamethasone</description>
    <arm_group_label>Dexamethasone group</arm_group_label>
    <other_name>dexamethsone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine Hydrochloride</intervention_name>
    <description>100 microgram dexmedetomidine</description>
    <arm_group_label>Dexmeteomidine group</arm_group_label>
    <other_name>dexmedetomidine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sixty healthy patients ASA I-II

          -  Aged 18-60 years

          -  Of both sexes

          -  Scheduled for shoulder arthroscopy using ultrasound interscalene block were enrolled.

        Exclusion Criteria:

          -  Patients with a history of any allergic reactions to levobupivacaine, dexamethasone or
             α2 agonists

          -  All patients with hypertension, cardiac, hepatic, renal or pulmonary diseases, -
             Patients who were under treatment by α2 agonist or antagonists

          -  Pregnant women

          -  Psychiatric patients

          -  Patients with a previous history or clinical evidence of central or peripheral
             neurological disease

          -  Coagulopathy or anticoagulant/antiaggregant therapy

          -  Contralateral phrenic nerve paresis

          -  Patients who have an infection at the site of the block.

          -  Every patient who had an anatomical or vascular abnormality in the upper extremity
             were excluded from this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>mamdouh e lotfy, m.d.</last_name>
    <role>Study Director</role>
    <affiliation>emeritus professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ashraf Eskandr</name>
      <address>
        <city>Shibīn Al Kawm</city>
        <state>Menoufiya</state>
        <zip>1234</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 10, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>May 6, 2019</last_update_submitted>
  <last_update_submitted_qc>May 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Menoufia University</investigator_affiliation>
    <investigator_full_name>ashraf magdy eskandr</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesia, ICU</investigator_title>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Interscalene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

